Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
AssigneeUniversity of Maryland, Baltimore
InventorsYun Qiu, Zhiyong Guo, Xi Yang
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.
Claims9
An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of
- (a) a human androgen receptor splice variant encoding AR3 polypeptide of SEQ ID NO:5;
- and
- (b) a polynucleotide sequence complementary to the polynucleotide sequence of (a).
An isolated nucleic acid molecule comprising a polynucleotide sequence selected from the group consisting of:
- (a) SEQ ID NO:1;
- and
- (b) the polynucleotide sequence complementary to the polynucleotide sequence of (a).
An isolated nucleic acid molecule comprising a polynucleotide encoding a fragment of SEQ ID NO:5 comprising at least 200 contiguous amino acids and including amino acids 630-645 of SEQ ID NO:5.
Dependencies are inferred from the claim text.